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 ABSTRACT 
Objective: Low-dose, long-term use of 14-membered macrolides is effective for 
treatment of patients with chronic airway inflammation such as diffuse panbronchiolitis 
or chronic rhinosinusitis. However, long-term use of macrolides can promote the growth 
of drug-resistant bacteria, and the development of anti-inflammatory macrolides that 
lack antibiotic effects is desirable. Previously, we developed EM900, a novel 12-
membered erythromycin A derivative, which has potent anti-inflammatory and 
immunomodulatory activities and lacks any antibacterial activity. We examined the 
anti-inflammatory effects of EM900 on mucus secretion from airway epithelial cells.  
Methods: To examine the in vivo effects of EM900 on airway inflammation, we 
induced hypertrophic and metaplastic changes of goblet cells in rat nasal epithelium via 
intranasal instillation of lipopolysaccharides. In vitro effects of EM900 on airway 
epithelial cells were examined using cultured human airway epithelial (NCI-H292) cells. 
Mucus secretion was evaluated via enzyme-linked immunosorbent assays with an anti-
MUC5AC monoclonal antibody. 
Results: Oral administration of EM900 or clarithromycin (CAM) significantly inhibited 
LPS-induced mucus production from rat nasal epithelium. EM900, CAM, or 
erythromycin significantly inhibited MUC5AC secretion induced by tumor necrosis 
factor-α from NCI-H292 cells. MUC5AC mRNA expression was also significantly 
lower in EM900-treated cells. 
Conclusion: These results indicated that a novel non-antibiotic macrolide, EM900 
exerted direct inhibitory effects on mucus secretion from airway epithelial cells, and 
that it may have the potential to become a new anti-inflammatory drug for the treatment 
of chronic rhinosinusitis.  
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 1. INTRODUCTION 
Low-dose, long-term use of a 14- or 15-membered macrolide such as 
clarithromycin (CAM), erythromycin (EM), or azithromycin (AZM) is a very effective 
treatment for patients with a chronic airway disease such as diffuse panbronchiolitis [1], 
chronic bronchitis [2,3], cystic fibrosis [4], or chronic rhinosinusitis (CRS) [5,6]. These 
useful clinical effects may depend on the anti-inflammatory activity of macrolides 
rather than the antibacterial activity. The anti-inflammatory activity includes the 
immunomodulatory effect on inflammatory cells, the modulation of cytokine production 
from epithelial cells, and the inhibition of bacterial functions and biofilm formation. 
Mucus hypersecretion is an important feature of airway inflammation, and 
macrolide therapy results in a significant reduction of the amount of secreted mucus; 
sputum and rhinorrhea. In previous studies, we demonstrated that macrolides inhibit 
hypersecretion of mucus in airways [7,8].  Intranasal instillation of lipopolysaccharides 
(LPS) causes inflammation of rat nasal epithelium, and oral administration of CAM, 
EM, or AZM significantly inhibits the LPS-induced hypertrophic and metaplastic 
changes of goblet cells in this rat model of airway inflammation. CAM, EM, or AZM 
also exerts direct inhibitory effects on mucus secretion from cultured airway epithelial 
(NCI-H292) cells or human nasal epithelial cells. These results indicate that low-dose, 
long-term macrolide therapy can be useful for the treatment of hypersecretory 
conditions associated with chronic airway inflammation. 
However, long-term use of macrolides can promote the growth of drug-
resistant bacteria, and non-antibiotic macrolide derivatives with anti-inflammatory 
activities are desirable. Recently, Sunazuka and coworkers developed a novel 12-
membered erythromycin A (EMA) derivative, (8R, 9S)-8, 9-dihydro-6, 9-epoxy-8, 9- 
anhydropseudoerythromycin A (EM900) that has potent anti-inflammatory and 
immunomodulatory activities, but apparently lacks antibacterial activity [9,10]. In that 
study, the anti-inflammatory activities of EMA derivatives were evaluated by the THP-
1 assay system, which examined the promotion of the differentiation of monocytes to 
macrophages.  
Here, we examined the anti-inflammatory effects of EM900 on mucus 
secretion from airway epithelial cells; specifically, we evaluated (1) the in vivo effects 
of EM900 on LPS-induced mucus production in rat nasal epithelium and (2) the in vitro 
effects of EM900 on tumor necrosis factor-α (TNF-α)-induced MUC5AC secretion and 
MUC5AC mRNA expression in cultured human airway epithelial (NCI-H292) cells. 
  
 2. MATERIALS AND METHODS 
2.1 Mucus Hypersecretion in Rat Nasal Epithelium 
 All experiments were approved by the Committee for the Care and Use of 
Laboratory Animals of Shiga University of Medical Science. LPS instillation was 
performed with rats as described previously [11]. Male Fischer 344 rats (6 weeks old) 
were anesthetized with ether, and 0.1 mL saline containing 0.1 mg LPS from 
Escherichia coli 0111:B4 (Sigma) or 0.1 mL saline control was intranasally instilled 
once-daily for three consecutive days. 
 EM900 was a gift from T. Sunazuka (Kitasato Institute for Life Sciences and 
Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan). 
EM900 (1-10 mg/kg) or CAM (10 mg/kg, Taisho Pharmaceutical, Tokyo) in 0.5% 
carboxymethyl cellulose sodium salt was administered orally exactly 1 h before the 
intranasal instillation of LPS on each of the three instillation days. Each rat was 
sacrificed 24 h after its last intranasal instillation; the nasal cavity was then transversely 
sectioned at the level of the incisive papilla. Paraffin sections were stained with alcian 
blue-periodic acid-Schiff (AB-PAS) or hematoxylin and eosin (H-E). 
2.2 Morphometry 
 The amount of AB-PAS-stained mucosubstance in the surface epithelium was 
determined with an image analyzer (Image-Pro Plus, Medical Cybernetics, Maryland) as 
described previously [11]. The area of nasal epithelium was outlined, and the image 
analyzer determined the area of AB-PAS-stained mucosubstances within this reference 
area. The percent area of stored mucosubstance per surface area was calculated over 2 
mm (1 mm each side of nasal septum) of the basal lamina at the center of the septal 
cartilage.  
2.3 Cell cultures   
A human mucoepidermoid carcinoma cell line, NCI-H292, was grown on 
plastic dishes in RPMI 1640 medium containing 10% fetal bovine serum, penicillin 
streptomycin (50 U/mL-50 µg/mL), and HEPES (25 mM). EM900, CAM, or EM was 
dissolved in N,N-dimethylformamide at a concentration of 10-1M, and each of these 
stock solutions was stored at 4 °C until use; each stock solution was diluted with the 
appropriate medium to result in a final concentration within the range between 10-4 and 
10-6 M in each experiment. When the NCI-H292 cells become confluent, TNF-α, and 
EM900 or CAM was added to the culture medium for 20 hours, then the culture 
medium was collected and total RNA was extracted from each culture. 
2.4 Enzyme-Linked Immunosorbent Assay (ELISA) 
Each subsample of culture medium and serial dilution of “standard” purified 
human nasal mucin [12] were incubated in one well of a 96-well plate at 40°C until dry. 
Wells were then incubated with 2% bovine serum albumin for 1h, and then with 50 µL 
of mouse monoclonal MUC5AC antibody (1:100, Thermo scientific, Massachusetts) for 
1 h. Wells were then incubated with 100 µL of horseradish peroxidase-goat anti-mouse 
IgG conjugate (1:10,000) for 1h. Color reaction was developed using 3,3’,5,5’-
tetramethylbenzidine peroxidase solution. Absorbance was read at 450 nm. Data were 
expressed as the percent above the control vehicle (RPMI-1640) as described previously 
[7,8].  
2.5 Reverse Transcription-Polymerase Chain Reaction (RT-PC) 
 Total RNA was extracted from cultured cells, reverse transcribed, then the 
cDNA was amplified by PCR using the Superscript preamplification system kit (Gibco, 
Grand Island, NY). The MUC5AC cDNA was amplified using the sense primer 5’-
CACCAAATACGCCAACAAGAC-3’ and the antisense primer 5’-
CAGGGCCACGCAGCCAGAGAA-3’. The GAPDH cDNA was amplified using the 
sense primer 5’-CCACCCATGGCAAATTCCATGGCA-3’ and the antisense primer 
5’-TCTAGACGGCAGGTCAGGTCCACC-3’. These steps were described previously 
[7]. 
2.6 Statistics 
 All data are expressed as mean ± standard error of the mean (SEM). Differences 
between variables were assessed via the Mann-Whitney U test. Probability values of 
p<0.05 were considered significant. 
 
  
 3. RESULTS 
In Vivo Effects of Macrolides on LPS-induced Mucus Production 
Intranasal instillation of LPS induced hypertrophic and metaplastic changes of 
goblet cells in rat nasal septal epithelium within 24 h after the last instillation (Figure 1). 
Only a few goblet cells were observed in untreated or saline-instilled control rats. Oral 
administration of EM900 (1-10 mg/kg) or CAM (10 mg/kg) inhibited LPS-induced 
hypertrophic changes of goblet cells, and quantitative measurement of the area of 
epithelial mucosubstance revealed a significant inhibition of intraepithelial mucus 
production in EM900- or CAM-treated rats (Figure 2).  
 The number of infiltrating neutrophils in nasal septal mucosa was significantly 
higher in LPS-treated rats than in saline-treated rats. Oral administration of EM900 or 
CAM slightly inhibited LPS-induced neutrophil infiltration, although these changes are 
statistically insignificant (Figure 3). 
In Vitro Effects of Macrolides on TNF-α-Induced MUC5AC Secretion  
TNF-α (20 ng/ml) stimulated the secretion of MUC5AC mucin from cultured 
NCI-H292 cells. At concentrations from 10-4 to 10-6 M, EM900 significantly inhibited 
TNF-α-induced MUC5AC secretion in a dose-dependent manner. CAM and EM 
showed inhibitory effects on TNF-α-induced MUC5AC secretion similar to those of 
EM900 (Figure 4). 
 Changes of MUC5AC gene expression were evaluated by RT-PCR; EM900 (10-
4 M) significantly inhibited TNF-α-induced MUC5AC mRNA expression in cultured 
NCI-H292 cells (Figure 5). 
  
 4. DISCUSSION 
    Low-dose, long-term use of 14-membered macrolides, EM or CAM [macrolide 
therapy], has been widely used for the treatment of patients with CRS in Japan [13]. 
Macrolide therapy is effective for hypersecretory conditions and for neutrophilic 
chronic inflammation of nasal cavity and paranasal sinuses. However, long-term use of 
macrolides can promote the growth of drug-resistant bacteria. A number of international 
and national surveillance studies have documented high levels of macrolide resistance 
in respiratory tract infection [14,15], and more than 70% of Streptococcus pneumoniae 
are resistant to EM in Japan [16]. Therefore, macrolide derivatives that have anti-
inflammatory activity, but lack antibacterial activity, would be highly useful because 
they should not promote growth of drug-resistant bacteria. 
Previously, non-antibiotic EMA derivatives, EM701 and EM703, were 
developed [17]. Based on THP-1 assays, the anti-inflammatory activities of EM701 and 
EM703 are stronger than that of EMA via promotion of monocytes to macrophages 
differentiation. However, EM701 and EM703 are unstable under acidic conditions; 
therefore, a novel EMA derivative with an acid-stable skeleton, EM900, was 
subsequently developed [9]. Based on THP-1 assays, EM900—like EM701 and 
EM703—has a stronger anti-inflammatory activity than EMA and lacks antibacterial 
activity against several representative bacteria. 
The purpose of the study describe here was to assess the anti-inflammatory 
activity of EM900, which is non-antibiotic. We demonstrated that oral administration of 
EM900 significantly inhibited LPS-induced mucus production and hypertrophic 
changes of goblet cells in rat nasal epithelium, and that EM900 directly suppressed 
TNF-α-induced MUC5AC secretion and MUC5AC mRNA expression in cultured 
airway epithelial cells. This is the first report demonstrating in vivo that EM900 has 
anti-inflammatory activity in nasal epithelium, and that EM900 exerts direct inhibitory 
effect on mucus secretion from airway epithelial cells.  
Hypertrophy and metaplasia of secretory cells in surface epithelium and 
submucosal glands result in hypersecretion of mucus. These are major factors in the 
pathogenesis of chronic airway inflammation. Clinical effectiveness of macrolide 
therapy is represented by the inhibition of the hypersecretory symptoms, such as sputum 
and rhinorrhea. We previously reported that EM, CAM, and AZM each attenuates LPS-
induced mucus production in rat nasal epithelium, and that each directly inhibits TNF-
α-induced MUC5AC secretion and MUC5AC mRNA expression in cultured airway 
epithelial cells [7,8]. In the present study, we demonstrated that the inhibitory effects on 
mucus secretion from airway epithelial cells in vivo and in vitro of EM900 were similar 
to those of EM, CAM, or AZM. These inhibitory actions appeared to be unique for 
EM900 and 14- or 15-membered macrolides because other antibiotics such as 
josamycin (16-membered macrolides) and ampicillin showed no such effect [7,8]. These 
results indicate that EM900 possesses anti-inflammatory activities similar to those of 
EM, CAM, or AZM, which are each effectively used for macrolide therapy.  
Reportedly, macrolide antibiotics reach higher concentrations in tissues and cells 
than in blood, and they diffuse extensively into respiratory tissues such as nasal mucosa 
and lung [18,19]. In the present study, oral administration of 1-10 mg/kg of EM900 or 
10 mg/kg of CAM significantly inhibited LPS-induced intraepithelial mucus production. 
These doses are similar to the clinical CAM dose, and are comparable with tissue 
concentrations of 10-4 to 10-5 M in rat airways [20]. EM900, CAM, or EM significantly 
inhibited TNF-α-induced MUC5AC secretion from cultured airway epithelial cells at 
concentrations from 10-4 to 10-5 M. TNF-α is one of the proinflammatory mediators that 
are induced by exposure to LPS in human airways. LPS stimulation enhances TNF-α/β 
production in rat lung [21], and a TNF-α antagonist inhibits LPS-induced mucus 
hypersecretion in rat nasal epithelium [22]. These results indicate that in vivo effects of 
EM900 or CAM on LPS-induced mucus production are caused in some part by a direct 
inhibitory effect on mucus secretion from airway epithelial cells. 
Recently, in vitro study has demonstrated that EM900 suppresses IL-1β-induced 
cytokines and mucin expression in airway epithelial (A549) cells; specifically, EM900 
(10-5 M) inhibits IL-1β-induced expression of IL-8, TNF-α, IL-1β, and MUC5AC 
mRNAs [23]. A NFκB–regulated transcriptional pathway is reportedly very important 
for IL-1β-induced MUC5AC expression [24]. At 10-5 M, EM900 or EM significantly 
inhibited IL-1β-induced NFκB activation. The inhibition of NFκB activation is one of 
the important anti-inflammatory activities of the 14-membered macrolides, CAM and 
EM; importantly, EM900 has a similar effect on airway epithelial cells.    
In conclusion, we induced hypertrophic and metaplastic changes of goblet cells in 
rat nasal epithelium by intranasal LPS instillation, and using this model of airway 
inflammation, we demonstrated that EM900 inhibited LPS-induced epithelial mucus 
production. We also demonstrated that EM900 directly inhibited TNF-α-induced 
MUC5AC secretion and MUC5AC mRNA expression in cultured NCI-H292 cells. 
These inhibitory effects of EM900 were similar to those of CAM or EM. These results 
indicate that a novel, non-antibiotic EMA derivative, EM900, has the potential to 
become a new anti-inflammatory drug for the treatment of chronic rhinosinusitis. 
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 FIGURES  
Figure 1.  
Light micrographs illustrating the nasal septal epithelium of rats. Bar=30 µm. 
(A) Saline-instilled control. (B) LPS-instilled rats (LPS rats). (C) EM900 (1 mg/kg)-
treated, LPS-instilled rats. (D) EM900 (10 mg/kg)-treated, LPS-instilled rats. (E) CAM 
(10 mg/kg)-treated, LPS-instilled rats. Hypertrophic and metaplastic changes of goblet 
cells were induced by LPS instillation. Oral administration of EM900 or CAM 
inhibited hypertrophic and metaplastic changes of goblet cells.  
 
Figure 2.  
Effects of EM900 (1-10 mg/kg) or CAM (10 mg/kg) on LPS-induced mucus 
production in rat nasal epithelium (n=6). LPS instillations resulted in a significant 
increase in intraepithelial mucosubstance within 24 h after three consecutive days of 
intranasal instillations. Oral administration of EM900 or CAM significantly inhibited 
LPS-induced mucus production. Data are shown as mean ± SEM. **p<0.01, * p<0.05. 
i.n., intranasal; p.o., per os.   
 
Figure 3.  
Effects of EM900 (1-10 mg/kg) or CAM (10 mg/kg) on neutrophil infiltration in 
rat nasal epithelium. The number of infiltrating neutrophils in nasal septal mucosa was 
significantly higher in LPS-treated rats than in saline-treated rats. Oral administration of 
EM900 or CAM slightly inhibited LPS-induced neutrophil infiltration, although these 
changes are statistically insignificant. Data are shown as mean ± SEM. n=6, **p<0.01. 
i.n., intranasal; p.o., per os. 
 
Figure 4.  
Effects of CAM, EM, or EM900 on TNF-α (20 ng/mL)-induced MUC5AC 
secretion from NCI-H292 cells (n=8). At concentrations from 10-4 M to 10-6 M, EM900 
significantly inhibited TNF-α-induced MUC5AC secretion in a dose-dependent manner. 
CAM and EM showed inhibitory effects on TNF-α-induced MUC5AC secretion similar 
to those of EM900. Data are expressed as the percent above the control vehicle (RPMI-
1640), and are shown as mean ± SEM. **p<0.01.  
 
Figure 5.  
Effects of EM900 on TNF-α (20 ng/mL)-induced MUC5AC mRNA expression 
from NCI-H292 cells (n=6). Total RNA was isolated and analyzed for MUC5AC and 
GAPDH mRNA expression by RT-PCR. EM900 significantly inhibited TNF-α-induced 
MUC5AC mRNA expression at 10-4M as demonstrated by the MUC5AC/GAPDH ratio. 
Data are shown as mean ± SEM. *p<0.05. 
 
 





